Zydus Lifesciences Ltd. (ZYDUSLIFE) fundamentals
Zydus Lifesciences Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as ZYDUSLIFE (ISIN INE010B01027). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Zydus Lifesciences Ltd. does
Zydus Lifesciences Limited is an India-based life-sciences company with positions across pharmaceuticals and consumer wellness, supported by a MedTech franchise and a global footprint across United States, India and other international markets. Its pharmaceutical business includes integrated pharmaceutical operations with business encompassing the entire value chain in research, development, production, marketing and distribution of pharmaceutical products. Its product portfolio includes active pharmaceutical ingredients, human formulations, and animal health and veterinary. Its consumer products business includes development, production, marketing and distribution of differentiated health and wellness products. It provides biologicals manufacturing sites offering contract development and manufacturing organization services to biopharmaceutical companies globally. Its focused therapy areas include cardiology, anti-diabetes, super specialty areas of oncology and nephrology, and others.
Valuation and market data
| Last close | ₹1119.10 |
|---|---|
| Market capitalisation | ₹1.12 lakh crore |
| Enterprise value | ₹1.19 lakh crore |
| P/E (TTM) | 22.34 |
| Price to book | 3.80 |
| Price to sales (TTM) | 2.32 |
| Book value per share | ₹294.80 |
| Dividend yield | 8.94% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Tue Apr 18 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹13,152 crore | ₹4,382 crore | ₹3,560 crore | 35.38 |
| Mar 2025 | ₹15,813 crore | ₹7,445 crore | ₹5,775 crore | 57.39 |
| Mar 2024 | ₹11,904 crore | ₹4,240 crore | ₹3,442 crore | 34.01 |
| Mar 2023 | ₹9,280 crore | ₹2,032 crore | ₹1,529 crore | 15.06 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 75.0% |
|---|---|
| Foreign institutions (FII) | 6.9% |
| Mutual funds | 5.1% |
| Other domestic institutions | 6.2% |
| Retail and others | 6.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.